GLP-1 RAs used by adults with type 2 diabetes and obesity is linked to lower risk for dementia, stroke, and mortality vs ...

Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...

For patients with type 2 diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with an increased ...

People using GLP-1 medications are more likely to suffer severe acid reflux, a new study suggests. Researchers found patients ...

Explore the growing GLP-1 agonists market, driven by rising diabetes and obesity rates. Discover advancements in therapies like Tirzepatide and GZR18, offering both glycemic control and weight loss ...

For adults with overweight or obesity, certain factors might influence weight loss after taking glucagon-like peptide 1 receptor agonists (GLP-1 RAs).

PolyPid's proprietary and clinically validated, prolonged-release drug delivery technology aims to subcutaneously deliver GLP ...

When patients were on a GLP-1 agonist for at least 1 year, they had a 30% lower risk for depression than DPP-4 inhibitor users (HR 0.70, 95% 0.59-0.82), and a trend towards a lower risk for ...

A clinical trial for semaglutide, the active ingredient in Ozempic, found that it improved blood sugar control in people with ...

Among patients with type 2 diabetes, use of GLP-1 receptor agonists with other blood sugar-lowering medications, such as sulfonylureas and insulin, may increase the chance of hypoglycemia. 6,7.

GLP-1 agonists and co-agonists conferred better respiratory and mortality outcomes among patients with COPD and type 2 diabetes. They also lowered recurrent risk for pneumonia, pulmonary edema and ...

Source Reference: Muayad J, et al "Comparative effects of GLP-1 receptor agonists and metformin on glaucoma risk in type 2 diabetes patients" Ophthalmology 2024; DOI: 10.1016/j.ophtha.2024.08.023.